Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy (DPN) is a common microvascular and neurologic complication of diabetes, typically affecting the feet and legs before the hands. It may cause burning pain, numbness, tingling, altered temperature sensation, weakness, and loss of protective sensation. Because symptoms can be subtle or absent, structured screening is important even when patients do not report discomfort. Clinical priorities include glycemic risk-factor management, regular foot assessment, prevention of ulcers and falls, treatment of neuropathic pain when present, and coordinated care for patients with complex disease.

DPN care is shifting from symptom treatment alone toward prevention, risk stratification, and longitudinal monitoring. Guidelines commonly support assessment of symptoms and signs using approaches such as monofilament testing, vibration assessment, reflex evaluation, and focused examination of skin, footwear, deformity, and vascular status. Integrated pathways increasingly connect primary care, diabetes services, podiatry, neurology, pain management, and wound care. Patient education, daily self-inspection, appropriate footwear, smoking cessation, physical activity, and management of blood pressure and lipids complement glucose management. These changes reflect the clinical reality that neuropathy, foot ulceration, infection, amputation risk, mobility limitation, and reduced quality of life are interrelated rather than isolated problems.

Artificial intelligence may support DPN management through image-based foot-risk assessment, analysis of electronic health records, symptom-trend monitoring, and decision support for referral or follow-up. Computer vision can help identify skin changes, wounds, swelling, or pressure-related abnormalities when images are captured consistently, while predictive models may combine laboratory results, comorbidities, prior ulcers, and sensory findings to prioritize review. These applications require representative validation across skin tones, devices, care settings, and disease severity. They should augment-not replace-clinical examination, preserve privacy, explain relevant outputs, and be monitored for false reassurance, missed high-risk findings, and unequal performance.

In North America, established diabetes services and multidisciplinary foot-care programs coexist with disparities in access, affordability, and continuity. Latin America faces a growing diabetes burden alongside variable availability of specialist assessment, preventive footwear, and wound services. Europe benefits from broad clinical guidance and structured health systems, but implementation differs across countries and populations. The Middle East is addressing high diabetes prevalence while expanding prevention, screening, and specialized care capacity. Africa faces substantial barriers involving diagnosis, workforce availability, essential medicines, and access to podiatric and wound care. Asia-Pacific contains highly diverse systems: several economies have advanced diabetes technology and specialist networks, while others continue to face late diagnosis, geographic barriers, and limited screening resources.

Across ASEAN, DPN priorities include improving diabetes detection, standardizing foot screening, and extending care beyond major cities. BRICS members face diverse epidemiologic and health-system conditions, making scalable primary-care protocols and affordable preventive services important. The European Union can benefit from cross-border exchange of clinical standards, digital-health safeguards, and chronic-disease care practices. G7 systems generally have strong clinical infrastructure but continue to address aging populations, multimorbidity, workforce pressure, and unequal access. GCC countries are focused on prevention and integrated chronic-care delivery amid substantial diabetes risk. NATO members span different health systems, yet common interests include continuity of care for mobile populations, rehabilitation capacity, and resilient supply and referral pathways.

Australia emphasizes primary-care screening, rural access, and culturally appropriate services, including for Indigenous communities. Brazil and Mexico face the need to expand consistent diabetes and foot-care delivery across geographically diverse populations. Canada and the United States have broad specialist capacity but continue to confront inequities, affordability barriers, and rural access challenges. China and India are prioritizing earlier diabetes identification, primary-care capacity, and scalable prevention across large populations. Japan and South Korea combine advanced clinical and digital infrastructure with the needs of aging populations. France, Germany, Italy, Spain, and the United Kingdom have established clinical services while working to improve pathway integration, waiting times, and outcomes for vulnerable groups. Russia’s priorities include strengthening chronic-disease monitoring, regional access, and continuity of preventive foot care.

Industry and health-system leaders should standardize minimum DPN screening elements, define referral thresholds, and embed reminders within routine diabetes visits. They should invest in workforce training for primary care, nursing, podiatry, and community health teams; improve access to therapeutic footwear and wound services; and use patient education that is culturally and digitally accessible. Programs should track process and outcome measures such as screening completion, timely referral, ulcer recurrence, avoidable admissions, mobility, pain, and patient-reported quality of life. Digital and AI tools should undergo prospective validation, equity testing, cybersecurity review, human oversight, and post-deployment monitoring. Partnerships with patients, caregivers, payers, and public-health organizations can improve adoption and continuity.

This executive summary is based on established clinical and public-health evidence concerning diabetes complications, peripheral neuropathy, diabetic foot risk, screening, prevention, and chronic-care delivery. The analytical approach synthesizes guidance from recognized medical authorities, peer-reviewed clinical and epidemiologic literature, and publicly available health-system information. Regional, group, and country observations are framed as contextual comparisons rather than quantitative market claims. Findings were screened to exclude unsupported commercial estimates, market sizing, market shares, forecasts, and company-specific assertions. AI-related discussion reflects documented clinical-use considerations and implementation requirements, not unvalidated performance claims.

DPN remains a clinically significant complication because sensory loss and pain can progress silently and contribute to ulceration, falls, disability, and avoidable limb-threatening events. The most durable response combines early detection, risk-factor management, patient self-care, appropriate footwear, rapid referral, and coordinated multidisciplinary follow-up. Regional and national differences mean that implementation must be adapted to local workforce, infrastructure, affordability, and cultural conditions. Artificial intelligence can help extend screening and prioritize care when rigorously validated and governed. Leaders who make preventive foot care routine, measurable, equitable, and connected to broader diabetes management are best positioned to improve patient outcomes.